New Alzheimer’s drug approved in Australia
A new medication, Donanemab – marketed as Kisunla – has been approved for use in Australia to help slow the progression of early-stage Alzheimer’s disease. Donanemab is an anti-amyloid monoclonal antibody designed to target and clear amyloid plaques in the brain, one of the key biological markers of Alzheimer’s. While not a cure, this treatment offers the potential to delay cognitive decline and support a better quality of life for individuals diagnosed in the early stages of the disease.
- TGA Approval:
The Therapeutic Goods Administration (TGA) in Australia has approved Donanemab (Kisunla) for use in patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
- Mechanism of Action:
Donanemab works by targeting and removing amyloid plaques, which are clumps of protein that accumulate in the brains of individuals with Alzheimer’s disease.
- Clinical Trials:
Clinical trials have shown that Donanemab can slow the progression of Alzheimer’s disease in the early stages.
- Administration:
Donanemab is administered as an intravenous infusion every four weeks for up to 18 months.
- PBS Listing:
While approved, Donanemab is not currently listed on the Pharmaceutical Benefits Scheme (PBS), meaning it’s not subsidized by the government and can be expensive.
- Cost:
The cost of Donanemab is estimated to be between $40,000 and $80,000 per year but is expected to be added to the Pharmaceutical Benefit Scheme.
Early Diagnosis:The TGA approval of Donanemab highlights the importance of early diagnosis to allow individuals to access treatment and support as soon as possible.
